Source:http://linkedlifedata.com/resource/pubmed/id/16304570
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2005-11-23
|
| pubmed:abstractText |
A total of 1111 children with acute myeloblastic leukaemia (AML) were treated in four consecutive Berlin-Frankfurt-Münster (BFM) studies from 1978 to 1998. The first cooperative trial AML-BFM 78 established intensive chemotherapy with seven drugs, CNS irradiation and 2-year maintenance, achieving a long-term survival (overall survival (OS)) of 40%. Induction intensification in AML-BFM 83 resulted in significant improvement of disease-free survival (DFS). The risk of haemorrhage, especially in children with hyperleukocytosis, proved the high relevance of supportive care. In AML-BFM 87, the benefit of CNS irradiation in preventing CNS/systemic relapses was demonstrated. In AML-BFM 93, the introduction of idarubicin during first induction followed by intensification with HAM increased the 5-year EFS, DFS and OS to 50+/-2, 61+/-3 and 57+/-2%, respectively. Stem cell transplantation (SCT), as applied in high-risk patients with a matched related donor, did not significantly improve the outcome compared to chemotherapy alone. In spite of treatment intensification, the therapy-related death rate decreased from trial to trial, mainly during induction. The future aim is to reduce long-term sequelae, especially cardiotoxicity, by administration of less cardiotoxic drugs, and toxicity of SCT by risk-adapted indications. The AML-BFM studies performed in three European countries with >70 cooperating centres have significantly improved the outcome in AML children; nevertheless, increasing experience with these intensive treatment regimens is of fundamental importance to reduce fatal complications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2030-42
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16304570-Adolescent,
pubmed-meshheading:16304570-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16304570-Antineoplastic Protocols,
pubmed-meshheading:16304570-Child,
pubmed-meshheading:16304570-Child, Preschool,
pubmed-meshheading:16304570-Cranial Irradiation,
pubmed-meshheading:16304570-Dose-Response Relationship, Drug,
pubmed-meshheading:16304570-Female,
pubmed-meshheading:16304570-Follow-Up Studies,
pubmed-meshheading:16304570-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16304570-Hemorrhage,
pubmed-meshheading:16304570-Humans,
pubmed-meshheading:16304570-Infant,
pubmed-meshheading:16304570-Infant, Newborn,
pubmed-meshheading:16304570-Leukemia, Myeloid, Acute,
pubmed-meshheading:16304570-Male,
pubmed-meshheading:16304570-Recurrence,
pubmed-meshheading:16304570-Remission Induction,
pubmed-meshheading:16304570-Risk Assessment,
pubmed-meshheading:16304570-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
|
| pubmed:affiliation |
Department of Haematology, Oncology, University Children's Hospital, Münster, Germany. ursula.creutzig.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|